Center for Biotechnology and Biomedicine, Cell Techniques and Applied Stem Cell Biotechnology, University of Leipzig, Deutscher Platz 5, 04103, Leipzig, Germany.
Cytotechnology. 2006 Mar;50(1-3):163-79. doi: 10.1007/s10616-006-6336-4. Epub 2006 Jun 23.
The liver is the most important organ for the biotransformation of xenobiotics, and the failure to treat acute or acute-on-chronic liver failure causes high mortality rates in affected patients. Due to the lack of donor livers and the limited possibility of the clinical management there has been growing interest in the development of extracorporeal liver support systems as a bridge to liver transplantation or to support recovery during hepatic failure. Earlier attempts to provide liver support comprised non-biological therapies based on the use of conventional detoxification procedures, such as filtration and dialysis. These techniques, however, failed to meet the expected efficacy in terms of the overall survival rate due to the inadequate support of several essential liver-specific functions. For this reason, several bioartificial liver support systems using isolated viable hepatocytes have been constructed to improve the outcome of treatment for patients with fulminant liver failure by delivering essential hepatic functions. However, controlled trials (phase I/II) with these systems have shown no significant survival benefits despite the systems' contribution to improvements in clinical and biochemical parameters. For the development of improved liver support systems, critical issues, such as the cell source and culture conditions for the long-term maintenance of liver-specific functions in vitro, are reviewed in this article. We also discuss aspects concerning the performance, biotolerance and logistics of the selected bioartificial liver support systems that have been or are currently being preclinically and clinically evaluated.
肝脏是外源物质生物转化的最重要器官,未能治疗急性或慢加急性肝衰竭会导致受影响患者的高死亡率。由于供体肝脏的缺乏和临床管理的可能性有限,人们越来越关注开发体外肝脏支持系统作为肝移植的桥梁或在肝衰竭期间支持恢复。早期提供肝脏支持的尝试包括基于使用常规解毒程序(如过滤和透析)的非生物疗法。然而,由于这些技术不能充分支持几种必需的肝脏特异性功能,因此在总体存活率方面未能达到预期的疗效。出于这个原因,已经构建了几种使用分离的有活力的肝细胞的生物人工肝脏支持系统,以通过提供必需的肝脏功能来改善暴发性肝功能衰竭患者的治疗效果。然而,尽管这些系统有助于改善临床和生化参数,但这些系统的对照试验(I/II 期)并没有显示出显著的生存益处。为了开发改进的肝脏支持系统,本文综述了体外长期维持肝脏特异性功能的细胞来源和培养条件等关键问题。我们还讨论了已在临床前和临床上进行评估或正在评估的选定生物人工肝脏支持系统的性能、生物相容性和物流方面的问题。